Original Article Superantigen involvement and susceptibility factors in Kawasaki disease: profiles of TCR Vβ2+ T cells and HLA-DRB1, TNF-α and ITPKC genes among Filipino patients

Magdalena F Natividad^{1,2}, Celia Aurora T Torres-Villanueva^{1,3}, Cynthia P Saloma¹

¹National Institute of Molecular Biology and Biotechnology, University of the Philippines, Diliman, Quezon City; ²Department of Microbiology and Parasitology, Far Eastern University-Dr. Nicanor Reyes Medical Foundation, Quezon City, Philippines; ³Current affiliation: CSIRO Marine and Atmospheric Research Division, Melbourne, Australia

Received February 19, 2013; Accepted March 6, 2013; Epub March 18, 2013; Published March 28, 2013

Abstract: Superantigens and genetic factors may play roles in the etiology and susceptibility to Kawasaki disease (KD). To investigate these roles, percentages of TCR-V β 2+ T cells were compared by flow cytometry using anti-V β 2 monoclonal antibodies and genotyping was done on *HLA-DRB1* exon 2, the -308 site of the *TNF-* α promoter region, and *ITPKC* SNP rs28493229 by polymerase chain reaction followed by direct sequencing. There were higher percentages of V β 2+ T-cells in KD patients (9.5 ± 2.15%) compared to healthy controls (7.25 ± 1.48%) (P<0.05, Student's t-test, n=6-8/group). However, no polymorphisms were observed in exon 2 of *HLA-DRB1* and in the -308 region of the *TNF-* α promoter. The *ITPKC* SNP rs28493229 G/C polymorphism was observed in 1 KD patient and 4 healthy controls. This study suggests that KD etiology may be associated with a superantigen and that *HLA-DRB1* exon2, *TNF-* α -308 region and *ITPKC* SNP rs28493229 may not be associated with KD. This is the first study investigating V β 2+ T cells and candidate genes involvement among Filipino KD patients.

Keywords: Superantigens, HLA-DRB1, TNF-α, ITPKC, Kawasaki disease

Introduction

Kawasaki disease (KD) is an acute potentially fatal multisystem vasculitis most commonly occurring in children less than 5 years of age [1]. It is considered as the most common cause of acquired heart disease in children that may lead to the development of coronary artery abnormalities when left untreated [1].

The causative agent of KD, which is believed to be infectious in nature, has not been identified. Studies have shown that KD may be caused by a superantigen (SAg), which causes a selective increase of T cells expressing particular Vβ gene segments [2-8]. Moreover, emerging lines of evidence suggest that genetic factors are involved in the susceptibility and outcome of KD. Asian children, especially those of Japanese, Chinese, and Korean descent, have the highest incidence of KD, although all racial groups are affected, strongly suggesting a genetic predisposition for KD [9]. The most probable candidate genes for susceptibility are those involved in immune reactions that characterize KD. such as HLA-DRB1. tumor necrosis factor-alpha (TNF-α) and inositol1.4.5triphosphate(IP3) kinase (ITPKC). SAgs bind not only with the V β region of the TCR but also with major histocompatibility (MHC) class II molecules expressed on antigen presenting cells (APCs) [10]. An elevation of TNF- α during the acute phase of KD has been implicated in the pathogenesis of vasculitis in KD [11-15]. Its levels are highest in children who develop coronary artery aneurysm (CAA) [15-17]. Polymorphisms in the promoter region of *TNF*- α have been associated with coronary artery disease (CAD) [18], coronary heart disease (CHD) [19], rheumatoid arthritis (RA) [20-22], rheumatic fever [23], and acute coronary syndrome (ACS) [24]. Some KD patients are known to develop CAD [25]. In a genome-wide study (GWAS) of KD, Onouchi et al identified a functional SNP (itpkc_3 G/C [rs28493229]) within intron 1 of the *ITPKC* gene to be associated with KD [26].

Studies such as these have not been done among Filipinos. We investigated if there was a significant increase in the percentage of TCR-V β 2+ T cells in KD patients compared to healthy controls to suggest SAg involvement, and if polymorphisms in *HLA DRB1* exon 2 (where most polymorphisms occur), the -308 polymorphism hotspot in the *TNF*- α promoter region and the functional SNP [rs28493229] in intron 1 of *ITPKC* were associated with susceptibility to KD.

Methodology

Two groups of patients were included in this study. The first group was composed of young children who were diagnosed clinically with KD with the following criteria: fever for at least 5 days, and four of the following five signs, (1) bilateral conjunctival injection without exudates; (2) changes in the oral mucosa, such as erythema and cracking lips, erythema of the pharynx, strawberry tongue; (3) changes in extremities, such as redness and swelling in the acute phase, periungual desquamation in the subacute phase; (4) polymorphous exanthema, and (5) cervical lymphadenopathy, (≥1.5 cm in diameter), usually unilateral. No other disease processes could explain the illness. Atypical cases were excluded.

These patients were referred to physicians at the Philippine Children's Medical Center, Quezon City, and the Far Eastern University-Dr Nicanor Reyes Medical Foundation Medical Center, Quezon City.

The second group was composed of healthy controls with ages ranging from 18 to 27 years, who were free of febrile disease for at least 4 weeks before examination and who were not under the influence of any treatment. Because it was difficult to obtain parental consent for the collection of blood samples from healthy young children, an older age group was used as healthy control. Van den Beemd *et al* showed that there is no difference in the V β 2 usage between age groups 0-15 years and 16-30 years, with both groups having a mean value of 7.9% [27].

Informed consent was obtained from the parents/guardians of the patients or from the healthy controls who have reached the age of majority at the time of sample collection. The research protocol was reviewed and approved by the Institutional Ethics Review Committee of the Far Eastern University-Dr. Nicanor Reyes Medical Foundation with approval number BS-F-005-2011.

Approximately 2 to 3 ml of peripheral blood were drawn using EDTA as anticoagulant within 10 days of the onset of fever from patients suspected of having KD and before the administration of IVIG, and anytime from healthy controls.

To determine the percentage of V β 2+ T cells, fluorescent activated cell sorting (FACS) was done to count CD3(+) T-cells by reacting them with FITC-conjugated anti-CD3 antibody (Clone IM1281, Immunotech, Marseille, France). Out of these CD3(+) T-lymphocytes, the percentages of those bearing TCR V β 2 were determined using phycoerythrin-conjugated monoclonal antibody (Clone MPB2D5, Immunotech, Marseille, France) against TCR V β 2.

To determine the polymorphisms in exon2 of HLA-DRB1, -308 site of the TNF- α promoter region and the ITPKC 1 SNP [rs28493229], genomic DNA was extracted from the blood samples using Genomic DNA Mini Kit Frozen Blood Protocol (Geneaid Biotech Ltd., Sijhih City, Taiwan). In this part of the study, 11 patients were added to the previous 6, constituting a total of 17 KD patients and 18 were added to the 8 with a total of 26 healthy controls. These genomic DNA extracts were used to amplify HLA-DRB1 exon 2, the TNF-α promoter containing the -308 region and the ITPKC intron 1 encompassing the functional SNP [rs28493229]. The sets of gene-specific primers used are shown on Table 1.

Gene amplification via polymerase chain reaction was performed using Promega Master Mix (Promega Corp, Wisconsin, USA) with the following PCR conditions for *HLA-DRB1*: initial denaturation at 95°C for 3 minutes and 35 cycles of 95°C for 30 s, 54°C for 30 s, and 72°C for 1.5 min, and a final extension step for 3 min at 72°C; for *TNF-* α promoter region: initial denaturation at 95°C for 3 minutes and 35 cycles of 95°C for 30 s, 55.3°C for 30 s, and 72°C for 1.5 min and a final extension step for 3 min at 72°C; and for *ITPKC* intron 1[rs28493229]: initial denaturation at 95°C for

Table 1. Prime	rs used in the	amplification	of the	gene regions
		ampinioacion		Source regione

	0 0			
Gene	Primer sequences	Amplicon size		
HLA-DRB1 exon 2				
Forward primer	5'-cagcacgtttcctgtggcag-3'	261 bp		
Reverse primer	5'-ctgtgaagctctccacaaccc -3'			
TNF-α promoter (-308)				
Forward primer	5'-gaaggaaacagaccacagacc -3'	187 bp		
Reverse primer	5'- ggggacacacaagcatca -3'			
ITPKC intron 1 [rs28493229]				
Forward primer	5'-ctggcactggtggtttccaaat-3'	500 bp		
Reverse primer	5'-aagaggttcccggagatgaaattg-3'			

Table 2. TCR V β 2+ T-cell expression in KD patients and healthy controls

	Day of illness blood	TCR V-beta2+ T cell/		
	was extracted	Total CD3+ T cell (%)		
KD Patients				
K01	8	10.3		
K03	6	8.6		
K04	8	10.9		
K05	6	12.4		
K06	8	8.5		
K07	10	6.3		
Healthy controls				
C01		8.8		
C02		6.6		
C03		5.1		
C04		7.2		
C05		9.7		
C06		6.5		
C7		6.3		
C08		7.8		

3 minutes and 35 cycles of 95°C for 30 s, 55.0°C for 30 s, and 72°C for 1.5 min and a final extension step for 3 min at 72°C. The PCR products were sent to FirstBASE Laboratories Sdn Bhd (Malaysia) for direct sequencing of forward and reverse strands using the same genespecific primers.

Student t-test was used to analyze the difference in the percentages of V β 2+ T cells between KD samples and those of healthy controls. A p-value of <0.05 is considered significant. Genotype and allele frequencies of SNP rs28493229 were determined by direct counting. Chi square test using Fisher's exact test was used to determine significance. Odds ratios and 95% confidence intervals were also calculated.

Results

The V β 2+ T-cell expression in 6 KD patients and 8 healthy controls are shown in **Table 1**.

The KD patients had V β 2+ T cell percentages that ranged from 6.3% to 12.4% while that of the healthy controls ranged from 5.1% to 9.7% (**Table 2**). There were higher percentages of V β 2+ T-cells in KD patients (9.5 ± 2.15%) compared to healthy controls (7.25 ± 1.48%) (P<0.05, Student's t-test, n=6-8/group) (**Table 3**).

No polymorphisms were observed in the DNA sequences of *HLA-DRB1* in both the KD and healthy controls. All KD sequences were those of DRB1*15:01:01:01 and healthy controls were also those of DRB1*15:01:01:01. Likewise, no polymorphisms were detected at the -308 position of the *TNF-* α promoter. We found that all KD patients and all controls had GG alleles at this position.

There were no differences in the genotype (OR=0.34, 95% CI=0.035-3.374, p=0.33) or allele (OR=0.36, 95% CI=0.39-3.401, p=0.34) frequencies of *ITPKC* SNP rs28493229 between controls and children with KD (**Table 4**). Only one out of 17 (5.9%) KD patients had G/C genotype and 4 out of 26 (15.4%) controls had the same genotype. Similarly, the *C* allele was found in only one KD (2.9%) patient and in 4 (7.7%) of the controls.

Discussion

Kawasaki disease is postulated to be caused by a SAg, which may be produced by a ubiquitous infectious agent. The infectious origin of KD has been hypothesized because of the nature of its clinical manifestations and epidemiological characteristics [1]. The SAg theory has been the subject of several investigations with conflicting results. The hallmark of a disease caused by a SAg-producing organism is the selective expansion of T cells bearing a par-

		Status	n	mean	SD	<i>p</i> -value
V-beta-2+ T cell/Total CD3+ T cell (%)		KD	6	9.50	2.151	0.038
		Control	8	7.25	1.475	
Table 4. Pol	ymorphism of rs2	28493229 of the /	TPKC gen	e in KD patients		
	KD, n=17 (%)	Control, n=26 (%)	OR	95% CI	X ² Fisher's Exact test p-value	
Genotype						
C/G	1 (20.0)	4 (80.0)	0.04 0.005 0.05		0.33	
G/G	16 (42.1)	22 (57.9)	0.34	0.035 - 3.374	0.33	
Allele						
С	1 (20.0)	4 (80.0)	0.00	0.39 - 3.401	0.34	
G	33 (40.7)	48 (59.3)	0.36			

 Table 3. Student's t-test analysis of V-beta-2+ T cells in KD patients

ticular β -chain variable gene segments [28, 29]. One group of investigators has shown positive evidence of SAg etiology showing either a selective expansion of V β 2- or V8-bearing T cells or the isolation of SAg-producing bacteria from the patients [3-5, 8, 30]. Another group, however, failed to demonstrate the above findings, neither were they able to find a significant difference in the presence of SAg-producing bacterial isolates among KD patients and control, nor did they see a pattern of increased V β family of T cells [31-33].

To investigate a SAg involvement in KD among Filipino patients, we performed fluorescence activated cell sorting (FACS) and found that KD patients have higher V β 2+Tcells compared to healthy controls, similar to the observation of Reichardt et al of elevated percentages of V β 2.1+ T cells in 7 confirmed KD patients compared to healthy controls [6]. Brogan et al demonstrated that 13 of 16 (81%) of their KD patients had either V β skewing and/or V β restricted activation involving V β 2.1 and V β 5.1 [34]. This is the first study that shows V β 2 profiles in Filipino KD patients.

Genetic factors may also be involved in the susceptibility to KD. A few studies have been conducted on the role of MHC class II in susceptibility in KD. Yoshioka et al previously reported that the frequencies of the DRB1*04051, *0406, and *0901 were high, whereas that of the DRB1*1101 was low among patients with KD as compared with the healthy adults [8]. We attempted to implicate polymorphisms in two candidate genes, namely, *HLA-DRB1* and *TNF*- α , with KD, both of which yielded negative results. The *HLA-DRB1* allele of all our 17 KD

patients was HLA-DRB1*15:01:01:01 and the same allele form was seen in all the 26 healthy controls. Similarly, Huang et al reported that the distribution of HLA-DRB1 allele families and alleles in children with KD did not differ from that in healthy controls in Taiwan [35]. Because the TNF- α gene locus lies within the HLA complex, we investigated its polymorphism specifically at the -308 position of its promoter with the aim of determining whether this region is influenced by the polymorphism in HLA-DRB1. TNF- α is involved in infectious and immunoinflammatory diseases such as KD. Different individuals may have different capacities for TNF- α production. TNF- α levels are elevated in the majority of children during the acute phase of KD [15, 16] and are highest in children who develop coronary artery aneurysm [15-17]. Most studies were concentrated in the promoter area of the TNF- α gene [36]. In our study, no polymorphism was observed at the -308 locus among the KD patients and healthy controls. These findings suggest that susceptibility to KD and coronary artery lesions may not be associated with the HLA-DRB1 and TNF-α gene.

~ ~

We did not find any significant difference in the genotype or allele frequencies of *ITPKC* SNP rs28493229 between controls and children with KD. Only one out of 17 (5.9%) KD patients had C/G genotype and 4 out of 26 (15.4%) had the same genotype. There was higher percentage (7.7%) of controls with C allele than those of the KD patients (2.9%). This is contrary to the findings of Onouchi et al [37] in their study among Japan and US patients, where C allele was present in greater frequency in KD patients than in healthy controls.

In conclusion, we show that there are Filipino patients who have elevated V β 2+ T cells compared to healthy controls, suggesting a possible involvement of a SAg in the etiology of KD. However, there was no difference in the polymorphisms found in *HLA-DRB1*, *TNF-* α and *ITPKC* genes between the two groups. Further studies on TCR-V β 2+ T-cells and genetic polymorphisms relating to susceptibility involving a larger cohort of Filipino patients would help elucidate the problem of KD etiology, pathogenesis, and susceptibility in the Philippines.

Acknowledgement

We thank Dr. Jaime A Santos of the Philippine Children's Medical Center and the Department of Child Health, FEU-Dr. Nicanor Reyes Medical Foundation for assistance in recruiting KD patients. This work is supported in part by the Office of the Vice Chancellor for Research and Development of the University of the Philippines, and by the Philippine Council for Health and Research Development, Department of Science and Technology, Philippines.

Address correspondence to: Magdalena F Natividad, Department of Microbiology and Parasitology, Far Eastern University-Dr. Nicanor Reyes Medical Foundation, Fairview, Quezon City, Philippines. Fax: 63 (02) 9835906; E-mail: mfnat118@yahoo.com

References

- Burns JC, Kushner HI, Bastian JF, Shike H, Shimizu C, Matsubara T, and Turner CL. Kawasaki Disease: A Brief History. Pediatrics 2000; 106: e27-34.
- [2] Abe A, Kotzin B, Jujo K, Melish M, Glode M, Kohsaka T and Leung DY. Selective expansion of T cells expressing t-cell receptor variable regions Vβ2 and Vβ8 in Kawasaki disease. Proc Natl Acad Sci U S A 1992; 89: 4066-4070.
- [3] Abe A, Kotzin B, Meissner C, Melish ME, Takahashi M, Fulton D, Romagne F, Malissen B and Leung DY. Characterization of T cell repertoire changes in acute Kawasaki diease. J Exp Med 1993; 177: 791-796.
- [4] Curtis N, Zheng R, Lamb JR and Levin M. Evidence for a superantigen mediated process in Kawasaki Disease. Arch Dis Child 1995; 72: 308-311.
- [5] Leung DY, Meissner C, Fulton D, Schlievert PM. The potential role of bacterial superantigens in the pathogenesis of Kawasaki syndrome. J Clin Immunol 1995; 15: 11S-17S.

- [6] Reichardt P, Lehmann I, Sierig G and Borte M. Analysis of T-cell receptor V-beta 2 in peripheral blood lymphocytes as a diagnostic marker for Kawasaki disease. Infection 2002; 30: 360-364.
- Yashimoro Y, Nagata S, Oguchi S and Shimizu T. Selective increase of V-beta 2+ T-cells in the small intestinal mucosa in Kawasaki disease. Pediatr Res 1996; 39: 264-266.
- [8] Yoshioka T, Matsutani T, Iwagami S, Toyosaki-Maeda T, Yutsudo T, Tsuruta Y, Suzuki H, Uemura WS, Takeuchi T, Koike M and Suzuki R. Polyclonal expansion of TCRBV2- and TCRBV6bearing T cells in patients with Kawasaki disease. Immunol 1999; 96: 465-472.
- [9] Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki Disease. Expert Rev Anti Infect Ther 2010; 8: 197-203.
- [10] Kotb M, Norrby-Teglund A, McGeer A, El-Sherbini H, Dorak MT, Khurshid A, Green K, Peeples J, Wade J, Thomson G, Schwartz B, Low DE. An immunogenetic and molecular basis for differences in outcomes of invasive group A streptococcal infections. Nat Med 2002; 8: 1398-1404.
- [11] Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, Kato H, Yabuta K. Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 1988; 48: 247-251.
- [12] Furukawa S, Matsubara T, Yone K, Hirano Y, Okumura K, Yabuta K. Kawasaki disease differs from anaphylactoid purpura and measles with regard to tumor necrosis factor-alpha and interleukin 6 in serum. Eur J Pediatr 1992; 51: 44-47.
- [13] Furukawa S, Matsubara T, Umezawa Y, Okumura K, Yabuta K. Serum levels of p60 soluble tumor necrosis factor receptor duringacute Kawasaki disease. J Pediatr 1994; 124: 721-725.
- [14] Lin CY, Lin CC, Hwang B, and Chiang BN. The changes of interleukin 2, tumor necrosis factor and gamma-interferon production among patients with Kawasaki disease. Eur J Pediatr 1991; 150: 179-182.
- [15] Matsubara T, Furukawa S, and Yabuta K. Serum Levels of Tumor necrosis factor, interleukin 2 receptor and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990; 56: 29-36.
- [16] Maury CPJ, Salo E, Pelkonen P. Elevated circulating tumor necrosis factor-a in patients with Kawasaki disease. J Lab Clin Med 1989; 113: 651-654.
- [17] Quasney MW, Bronstein DE, Cantor RM, Zhang Q, Stroupe C, Shike H, Bastian JF, Matsubara T,

Fujiwara M, Akimoto K, Newburger JW, Burns JC. Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease. Pediatr Res 2001; 49: 686-90.

- [18] Sbarsi I, Falcone C, Boiocchi C, Campo I, Zorzetto M, De Silvestri A, Cuccia M. Inflammation and atherosclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease. Int J Immunopathol Pharmacol 2007; 20: 145-54.
- [19] Vendrell J, Fernandez-Real JM, Gutierrez C, Zamora A, Simon I, Bardaji A, Ricart W, Richart C. A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis 2003; 167: 257-64.
- [20] Date Y, Seki N, Kamizono S, Higuchi T, Hirata T, Miyata K, Ohkuni M, Tatsuzawa O, Yokota S, Joo K, Ueda K, Sasazuki T, Kimura A, Itoh K and Kato H. Identification of a genetic risk factor for systemic juvenile arthritis in the 5'-flanking region of the TNF- α gene and HLA genes. Arthritis and Rheumatism 1999; 42: 2577-2582.
- [21] Fonseca JE, Cavaleiro J, Teles J, Sousa E, Andreozzi VL, Antunes M, Amaral-Turkman MA, Canhão H, Mourão AF, Lopes J, Caetano-Lopes J, Weinmann P, Sobral M, Nero P, Saavedra MJ, Malcata A, Cruz M, Melo R, Braña A, Miranda L, Patto JV, Barcelos A, da Silva JC, Santos LM, Figueiredo G, Rodrigues M, Jesus H, Quintal A, Carvalho T, Pereira da Silva JA, Branco J and Queiroz MV. Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter. Arthritis Res & Thera 2007; 9: R37-46.
- [22] Seki N, Kamizono S, Yamada A, Higuchi T, Matsumoto H, Niiya F, Kimura A, Tsuchiya K, Suzuki R, Date Y, Tomita T, Itoh K, Ochi T. Polymorphisms in the 5'-flanking region of tumor necrosis factor-alpha gene in patients with rheumatoid arthritis. Tissue Antigens 1999; 54: 194-197.
- [23] Ramasawmy R, Faé KC, Spina G, Victora GD, Tanaka AC, Palácios SA, Hounie AG, Miguel EC, Oshiro SE, Goldberg AC, Kalil J, Guilherme L. Association of polymorphisms within the promoter region of the tumor necrosis factor-alpha with clinical outcomes of rheumatic fever. Mol Immunol 2007; 44: 1873-8.
- [24] Dedoussis GV, Panagiotakos DB, Vidra NV, Louizou E, Chrysohoou C, Germanos A, Mantas Y, Tokmakidis S, Pitsavos C, Stefanadis C. Association between TNF-alpha -308G>A polymorphism and the development of acute coronary syndromes in Greek subjects: the

CARDIO2000-GENE Study. Genet Med 2005; 7: 411-6.

- [25] Rowley AH and Shulman ST. Kawasaki Syndrome. Clin Microbiol Rev 1998; 11: 405-414.
- [26] Onouchi Y, Tamari M, Takahashi A, Tsuboda T, Yashiro M, Nakamura Y, Yanagawa H, Wakui K, Fukushima Y, Kawasaki T, Nakamura Y and Hata A. A genomewide linkage analysis of Kawasaki disease: Evidence of linkage to chromosome 12. J Hum Genet 2007; 52: 179-190.
- [27] Van den Beemd R, Boor PPC, van Lochem EG, Hop WCJ, Langerak AW, WolversTettero YYM, et al. Flow cytometric analysis of the VB repertoire in healthy controls. Cytometry 2000; 40: 336-345.
- [28] Yeung RSM. Kawasaki Disease: An Update. HK J Pediatr 2005; 19: 238-244.
- [29] Barron KS. Kawasaki Disease: Etiology, pathogenesis, and treatment. Cleveland Clin J Med 2002; 69: 69-77.
- [30] Leung DY, Meissner HC, Fulton D, Murray DL, Kotzin BL and Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342: 1385-1388.
- [31] Pietra B, De Inocencio J, Gianini EH and Hirsch R. TCR V Beta family repertoire and T cell activation markers in Kawasaki Disease. J Immunol 1994; 53: 1881-1888.
- [32] Mancia L, Wahlström J, Schiller B, Chini L, Elinder G, D'Argenio P, Gigliotti D, Wigzell H, Rossi P, Grunewald J. Characterization of the T cell ReceptorV-B Repertoire in Kawasaki Disease. Sacn J Immunol 1998; 48: 443-449.
- [33] Choi Y, Lafferty JA, Clements JR, Todd JK, Gelfand EW, Kappler J, Marrack P, Kotzin BL. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J exp Med 1990; 172: 981-984.
- [34] Brogan PA, Shah V, Klein N, Dillon MJ. V-betarestricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury. Arthritis Rheum 2004; 50: 589-597.
- [35] Huang FY, Chang TY, Chen MR, Hsu CH, Lee HC, Lin SP, Kao HA, Chiu NC, Chi H, Liu TY, Liu HF, Dang CW, Chu CC, Lin M, Sung TC, Lee YJ. Genetic variations of HLA-DRB1 and susceptibility to Kawasaki disease in Taiwanese children. Hum Immunol 2007; 68: 69-74.
- [36] Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K. Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-a gene in Japanese. Tissue Antigens 1998; 1: 605-612.
- [37] Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, Nakamura Y, Yanagawa H, Wakui K, Fukushima Y, Kishi F, Hamamoto K, Terai M, Sato Y, Ouchi K, Saji T, Nariai A, Ka-

buragi Y, Yoshikawa T, Suzuki K, Tanaka T, Nagai T, Cho H, Fujino A, Sekine A, Nakamichi R, Tsunoda T, Kawasaki T, Nakamura Y, Hata A. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysm. Nat Genet 2008; 40: 35-42.